Northwestern University

Sarki A Abdulkadir

Gary E Schiltz

Atul D Jain

Huiying Han

Rama K Mishra

Javier Izquierdo-Ferrer

Praveen Thumbikat

Jonathan F Anker

Anthony J Schaeffer

Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.

Substituted heterocycles as c-MYC targeting agents

Disclosed are proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein. The disclosed PROTACs typically include a first targeting moiety that binds to c-MYC (M) which may be derived from a substituted heterocycle that binds to c-MYC such as a substituted pyrazole. The first targeting moiety typically is linked via a bond or a linker (L) to a second targeting moiety that binds to an E3 ubiquitin ligase (M). As such, the disclosed PROTACS may be described as having a formula M-L-Mor M-L-M.

Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein

Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1is administered for the treatment of prostate cancer.

Immunostimulatory bacteria for the treatment of cancer

Growing community of inventors

Lombard, IL, United States of America

Sarki A Abdulkadir